| 前收市價 | 1.7650 |
| 開市 | 1.8380 |
| 買盤 | 1.7960 x 無 |
| 賣出價 | 1.9950 x 無 |
| 今日波幅 | 1.7420 - 1.9280 |
| 52 週波幅 | 1.2940 - 9.4050 |
| 成交量 | |
| 平均成交量 | 125,092 |
| 市值 | 485.426M |
| Beta 值 (5 年，每月) | 0.66 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -4.5700 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
- Reuters
CORRECTED-UPDATE 1-European shares dip ahead of ECB policy decision
European shares slipped on Thursday as investors avoided big bets ahead of a monetary policy decision by the European Central Bank and remarks by ECB's Christine Lagarde on the outlook for interest rate cuts. The pan-European STOXX 600 lost 0.3%, as of 0906 GMT.
- Reuters
Viatris forecasts strong 2024 sales on higher demand for branded drugs
Drugmaker Viatris forecast annual revenue above Wall Street estimates on Wednesday, banking on strong demand for its branded drugs such as Yupelri for lung disease and Breyna for asthma. Viatris was formed with the merger of Mylan and Pfizer's Upjohn business and has generic and key branded drugs in its portfolio, including erectile dysfunction drug Viagra, anti-anxiety medication Xanax, epilepsy treatment Lyrica and arthritis treatment Celebrex. CEO Scott Smith said Viatris would focus on growing its base business, which consists of its generic and branded drugs portfolio, this year, including through research partnerships such as its deal with Switzerland-based biotech Idorsia that was announced earlier on Wednesday.
